BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Georgel AF, Cayet D, Pizzorno A, Rosa-Calatrava M, Paget C, Sencio V, Dubuisson J, Trottein F, Sirard JC, Carnoy C. Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir. Antiviral Res 2019;168:28-35. [PMID: 31078648 DOI: 10.1016/j.antiviral.2019.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Manan A, Pirzada RH, Haseeb M, Choi S. Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. IJMS 2022;23:10716. [DOI: 10.3390/ijms231810716] [Reference Citation Analysis]
2 Nuñez-Ortiz N, Díaz-Rosales P, García JA, Serra CR, Enes P, Tafalla C, Gomez-Casado E. Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout. Fish Shellfish Immunol 2022:S1050-4648(22)00492-2. [PMID: 35981702 DOI: 10.1016/j.fsi.2022.08.018] [Reference Citation Analysis]
3 Girkin JLN, Maltby S, Bartlett NW. Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell. Eur Respir Rev 2022;31:210274. [PMID: 35508333 DOI: 10.1183/16000617.0274-2021] [Reference Citation Analysis]
4 Ruffin M, Bigot J, Calmel C, Mercier J, Givelet M, Oliva J, Pizzorno A, Rosa-Calatrava M, Corvol H, Balloy V, Terrier O, Guillot L. Flagellin From Pseudomonas aeruginosa Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by Increasing TMPRSS2 Expression. Front Immunol 2021;12:714027. [PMID: 34950129 DOI: 10.3389/fimmu.2021.714027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mabrey FL, Morrell ED, Wurfel MM. TLRs in COVID-19: How they drive immunopathology and the rationale for modulation. Innate Immun 2021;27:503-13. [PMID: 34806446 DOI: 10.1177/17534259211051364] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Jafarpour R, Pashangzadeh S, Dowran R. Host factors: Implications in immunopathogenesis of COVID-19. Pathol Res Pract 2021;228:153647. [PMID: 34749207 DOI: 10.1016/j.prp.2021.153647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Nassar A, Ibrahim IM, Amin FG, Magdy M, Elgharib AM, Azzam EB, Nasser F, Yousry K, Shamkh IM, Mahdy SM, Elfiky AA. A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses. Molecules 2021;26:6455. [PMID: 34770863 DOI: 10.3390/molecules26216455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
8 Maguire PT, Loughran ST, Harvey R, Johnson PA. A TLR5 mono-agonist restores inhibited immune responses to Streptococcus pneumoniae during influenza virus infection in human monocytes. PLoS One 2021;16:e0258261. [PMID: 34644311 DOI: 10.1371/journal.pone.0258261] [Reference Citation Analysis]
9 Nedeljković M, Sastre DE, Sundberg EJ. Bacterial Flagellar Filament: A Supramolecular Multifunctional Nanostructure. Int J Mol Sci 2021;22:7521. [PMID: 34299141 DOI: 10.3390/ijms22147521] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
10 Yin H, Jiang N, Shi W, Chi X, Liu S, Chen JL, Wang S. Development and Effects of Influenza Antiviral Drugs. Molecules 2021;26:810. [PMID: 33557246 DOI: 10.3390/molecules26040810] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
11 Gadanec LK, McSweeney KR, Qaradakhi T, Ali B, Zulli A, Apostolopoulos V. Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells? Int J Mol Sci 2021;22:992. [PMID: 33498183 DOI: 10.3390/ijms22030992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 55] [Article Influence: 16.0] [Reference Citation Analysis]
12 Baghbani T, Nikzad H, Azadbakht J, Izadpanah F, Haddad Kashani H. Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19. Microb Cell Fact. 2020;19:217. [PMID: 33243230 DOI: 10.1186/s12934-020-01483-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
13 Clark B, Poulton K. SARS-CoV-2: An immunogenetics call to arms. Int J Immunogenet 2020;47:319-23. [PMID: 32654378 DOI: 10.1111/iji.12504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chakraborty C, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G. Consider TLR5 for new therapeutic development against COVID-19. J Med Virol 2020;92:2314-5. [PMID: 32391920 DOI: 10.1002/jmv.25997] [Cited by in Crossref: 31] [Cited by in F6Publishing: 41] [Article Influence: 15.5] [Reference Citation Analysis]
15 Golonka RM, Saha P, Yeoh BS, Chattopadhyay S, Gewirtz AT, Joe B, Vijay-Kumar M. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. Physiol Genomics. 2020;52:217-221. [PMID: 32275178 DOI: 10.1152/physiolgenomics.00033.2020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 21.0] [Reference Citation Analysis]